Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025

Published by KuicK Research Product code 954552
Published Content info 250 Pages
Delivery time: 1-2 business days
Price
Back to Top
Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025
Published: August 20, 2020 Content info: 250 Pages
Description

"Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025" Report highlight:

  • Diabetes Drug Market Opportunity: > US$ 1.5 Billion by 2025
  • Diabetes Device Market Opportunity: > US$ 1 Billion by 2025
  • Glucose Monitoring Device Market Absolute Growth: 33% (2019-2025)
  • Oral Hypoglycemic Drugs Market - Availability, Dosage & Price Analysis
  • Insulin Availability, Dosage & Price Analysis
  • Insulin Delivery Device Market - Availability, Price & Sales Analysis
  • Glucose Monitoring Device Market - Availability & Price Analysis
  • Investments & Collaborations by Leading Market Players

Over the past few years, Saudi Arabia has witnessed exponential economic growth and fortune, which is followed by the swift technological transformation that resulted in major undesirable effects on lifestyle. Consequently, the prevalence of physical inactivity, obesity and sedentary behaviors along with the consumption of high caloric diet, and sugar-sweetened beverages went on the increase and became very common among Saudi society.

The diabetes incidences are increasing rapidly among the kingdom population and the same is expected to remain consistent in upcoming year due to presence of high percentage of obese and overweight population. Unhealthy lifestyle and lack of physical activities are two major factors responsible for the development of diabetes at early age in Saudi Arabian children and it is further observed that the prevalence rate of juvenile diabetes has been increasing continuously during the past few years. Driven by above mentioned factors, the diabetic burden in Saudi Arabia is expected to increase with higher momentum in future, which will ultimately lead to exponential demand of antidiabetic drugs there by driving the overall diabetes drug and insulin delivery market in coming years.

Several different initiatives and programs are undertaken by the regulatory bodies for supporting the diabetic patients in Saudi Arabia. Increasing diabetes patients, drug development in the field of diabetes, presence of generic drugs, government support, technological advancement, rising geriatric population, rising awareness and increasing healthcare and expenditure are the factors that are driving the diabetes market. The pipeline that the country's research and development center is holding is expected to double the market size at tremendous rate in the near future. Already the market is flooded with several branded and generic diabetes drugs and soon it will be joined by another large numbers of promising diabetes drugs. Various stake holders of the Saudi Arabia diabetes market are constantly working on the best possible treatment therapies for the diabetic population. To accompany this, the government has also started some healthcare missions that aims at providing the best healthcare solution to the patients who are in the urgent need of a treatment or who have failed earlier treatments. This whole covers a larger portion of the diabetes mellitus patients as a big part of the mission covers arrival of generic drug makers in the country and focusing towards the disease that are observed in larger percentage.

The diabetic population has widely accepted the presence of branded and imported drugs in the country driven by the socio economic parameters, which are apparently leading to accelerating growth of the branded diabetes drugs market in the country. In addition to the presence of branded drugs, the market is also observing an increase in the number of home grown pharmaceutical companies and distributors engaged in research, development and distribution of diabetes drugs in the market.

As per the report findings, it is estimated that soon the market will flourish in all the parameters that are important for a market to dominate the entire diabetes market. Strong brand loyalty and increasing lifestyle diseases are some of the factors that are expected to drive the diabetes drug market in the upcoming timeframe. Furthermore, the country is experiencing growing healthcare infrastructure, increasing per capita income and a large influx of health insurance companies which are estimated to fuel the growing diabetes market. Such huge penetration of the parameters responsible for market growth is estimated to develop a strong and competitive landscape for the future diabetes market.

Table of Contents

Table of Contents

1. Introduction to Saudi Arabia Diabetes Market

  • 1.1 Overview
  • 1.2 Current Market Scenario

2. Saudi Arabia - Diabetes Prevalence & Statistics

  • 2.1 By Population
  • 2.2 By Diabetes Type
    • 2.2.1 Type 1 Diabetes
    • 2.2.2 Type 2 Diabetes
  • 2.3 By Age & Gender
  • 2.4 Obesity & Overweight

3. Saudi Arabia - Pharmaceutical Pricing & Reimbursement Policies

  • 3.1 Pricing Policies
    • 3.1.1 In-Patent Pharmaceuticals
    • 3.1.2 Off-Patent, Generics & Other Locally Manufactured Product
    • 3.2 Procurement & Reimbursement Policies

4. Saudi Arabia - Regulatory Aspects of Pharmaceutical Products

  • 4.1 Gulf Central Committee for Drug Registrations (GCC-DR)
  • 4.2 Regulatory Review Process
  • 4.3 Centralized Registration
  • 4.4 Decentralized Drug Registration Regulation

5. Saudi Arabia - Diabetes Drug Market

  • 5.1 Market Analysis
  • 5.2 Prescription Pattern

6. Saudi Arabia - Oral Hypoglycemic Drugs Market - Availability, Dosage & Price Analysis

  • 6.1 Biguanides (Metformin Hydrochloride)
    • 6.1.1 Glucophage
    • 6.1.2 Glucare XR
    • 6.1.3 Dimetor
    • 6.1.4 Formit XR
  • 6.2 Sulfonylurea
    • 6.2.1 Gliclazide
    • 6.2.2 Glimepiride
    • 6.2.3 Glibenclamide
  • 6.3 DPP-4 Inhibitors
    • 6.3.1 Vildagliptin
    • 6.3.2 Saxagliptin (Onglyza)
    • 6.3.3 Sitagliptin (Januvia)
  • 6.4 SGLT2 Inhibitors
    • 6.4.1 Canagliflozin (Invokana)
    • 6.4.2 Dapagliflozin (Forxiga)
    • 6.4.3 Empagliflozin (Jardiance)
  • 6.5 Others
    • 6.5.1 Meglitinides
    • 6.5.2 Thiazolidinediones
    • 6.5.3 α-Glucosidase Inhibitors
  • 6.6 Combinational Drugs
    • 6.6.1 Metformin & Sulfonylurea Combination
    • 6.6.2 Metformin & DPP-4 Inhibitors Combination
    • 6.6.3 Metformin & SGLT-2 Inhibitors Combination

7. Saudi Arabia Insulin Market - Availability, Dosage & Price Analysis

  • 7.1 Lantus
  • 7.2 Humulin
    • 7.2.1 Humulin 70/30 100U/ml
    • 7.2.2 Humulin N-NPH
  • 7.3 Humalog
  • 7.4 Mixtard
  • 7.5 Apidra
  • 7.6 Insulatard

8. Saudi Arabia - Diabetes Device Market Analysis

9. Saudi Arabia Insulin Delivery Device Market - Availability, Price & Sales Analysis

  • 9.1 Insulin Syringes
  • 9.2 Insulin Pen
    • 9.2.1 Humalog KwikPen
    • 9.2.2 Flexpen
    • 9.2.3 Solostar
    • 9.2.4 NovoPen
    • 9.2.5 Others
  • 9.3 Insulin Pumps
  • 9.4 Insulin Jet Injectors

10. Saudi Arabia - Glucose Monitoring Device Market - Availability & Price Analysis

  • 10.1 Self-Monitoring Blood Glucose Devices
  • 10.2 Continuous Glucose Monitoring Device

11. Saudi Arabia Diabetes Market - Clinical Insight

12. Saudi Arabia Diabetes Market - Investments & Collaborations by Leading MNCs

13. Saudi Arabia Diabetes Market Dynamics

  • 13.1 Market Drivers
  • 13.2 Challenges for Saudi Arabia Diabetes Market

14. Saudi Arabia Diabetes Drug Market Future Outlook

15. Competitive Landscape

  • 15.1 Abbott
  • 15.2 Aljazeera Pharmaceutical Industries
  • 15.3 Al Mojil Drug Company
  • 15.4 AstraZeneca
  • 15.5 Bayer
  • 15.6 CAD Middle-East Pharmaceutical Company
  • 15.7 Eli - Lilly
  • 15.8 Julphur Pharmaceuticals
  • 15.9 Kuwait Saudi Pharmaceutical Company
  • 15.10 Merck
  • 15.11 Novartis
  • 15.12 Oman Pharmaceuticals
  • 15.13 Roche
  • 15.14 Saja Pharmaceuticals
  • 15.15 Sanofi
  • 15.16 Servier
  • 15.17 SPIMACO Addwaeih
  • 15.18 Tabuk Pharmaceuticals
  • 15.19 Qatar Life Pharma
  • 15.20 YIACO Medical Company

List of Figures

  • Figure 1-1: Adult Diabetic Population - MEA v/s Saudi Arabia (Million), 2019
  • Figure 1-2: Adult Diabetic Population - Saudi Arabia v/s Rest of MEA (%), 2019
  • Figure 1-3: Adult Diabetic Population - GCC v/s Saudi Arabia (Million), 2019
  • Figure 1-4: Adult Diabetic Population - Saudi Arabia v/s Rest of GCC (%), 2019
  • Figure 1-5: Saudi Arabia Healthcare Expenditure - Total v/s Diabetes (US$ Billion), 2018
  • Figure 1-6: Saudi Arabia Healthcare Expenditure - Diabetes v/s Other Diseases (%), 2018
  • Figure 1-7: Middle East - Diabetes Drug Market Opportunity (US$ Billion), 2019-2025
  • Figure 1-8: Middle East v/s Saudi Arabia - Diabetes Drug Market Size (US$ Billion), 2019
  • Figure 1 9: Saudi Arabia - Diabetes Device Market Size - Total v/s Blood Glucose Monitoring Device (US$ Million), 2019
  • Figure 2-1: Saudi Arabia - Adult Diabetic Population (Million), 2017 & 2019
  • Figure 2-2: Saudi Arabia - Estimated Number of Adult Diabetic Population (Million), 2030 & 2045
  • Figure 2-3: Saudi Arabia Adult Diabetic Population - Diagnosed v/s Undiagnosed (Million), 2019
  • Figure 2-4: Saudi Arabia - Adult Diabetic Population Share - Diagnosed v/s Undiagnosed (%), 2019
  • Figure 2-5: Saudi Arabia - Population Estimates (Million), 2019, 2020, 2025 & 2030
  • Figure 2-6: Saudi Arabia Population by Age (Million), 2019
  • Figure 2-7: Saudi Arabia - Adult Population (Million), 2019, 2030 & 2045
  • Figure 2-8: Saudi Arabia - Age Adjusted Diabetes Prevalence Rate (%), 2019, 2025 & 2045
  • Figure 2-9: Saudi Arabia - Diabetes Related Deaths, 2010 & 2019
  • Figure 2-10: Saudi Arabia - Adult Diabetes Cases by Type (Million), 2019
  • Figure 2-11: Saudi Arabia - Diabetes Cases by Type (%), 2019
  • Figure 2-12: Saudi Arabia - Type 1 Diabetic Adult Population (Million), 2019, 2025 & 2045
  • Figure 2-13: Saudi Arabia - Total & Newly Diagnosed Type 1 Diabetic Cases in Age below 19 Years, 2019
  • Figure 2-14: Saudi Arabia - Type Diabetic Population (Million), 2019, 2025 & 2045
  • Figure 2-15: Saudi Arabia - Diabetes Prevalence Rate by Gender (%), 2016
  • Figure 2-16: Saudi Arabia - Diabetic Population by Gender (Million), 2016
  • Figure 2-17: Saudi Arabia - Diabetes Cases by Age (%), 2017
  • Figure 2-18: Saudi Arabia - Newly Diagnosed Type 1 Diabetes Cases in Children by Age, 2019
  • Figure 2-19: Saudi Arabia - Type 1 Diabetes Cases in Children by Age, 2019
  • Figure 2-20: Saudi Arabia - Type 1 Diabetes Cases in Children by Age (%), 2019
  • Figure 2-21: Saudi Arabia - Obesity Prevalence Rate (%), 2016 & 2019
  • Figure 2-22: Saudi Arabia - Obese Population (Million), 2016 & 2019
  • Figure 2-23: Saudi Arabia - Obesity Prevalence Rate by Gender (%), 2016
  • Figure 2-24: Saudi Arabia - Overweight Prevalence Rate by Gender (%), 2016
  • Figure 2-25: Saudi Arabia - Physical Inactivity Prevalence Rate by Gender (%), 2016
  • Figure 4-1: Saudi Arabia - Types of Drug Registration Process
  • Figure 4-2: Process Map for GCC Centralized Registration
  • Figure 4-3: GCC - Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US$), 2019
  • Figure 4-4: GCC - Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US$), 2019
  • Figure 4-5: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Innovative/Biological Products (SAR/US$), 2019
  • Figure 4-6: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Generic Products (SAR/US$), 2019
  • Figure 4-7: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength & New Pack Size for Intravenous Generic Products (SAR/US$), 2019
  • Figure 4-8: Saudi Arabia - Regulatory Process for Pharmaceuticals
  • Figure 5-1: Saudi Arabia - Diabetes Drug Market Size (US$ Million), 2019 - 2025
  • Figure 5-2: Saudi Arabia - Patients on Single, Double & Triple Drug Therapy for Diabetes Management (%), 2018
  • Figure 5-3: Saudi Arabia - Prescription Share of Anti-Diabetic Drugs (%), 2018
  • Figure 5-4: Saudi Arabia - Sulfonylurea Drug's Prescription Share by products (%), 2018
  • Figure 5-5: Saudi Arabia - Insulin Prescription Share by Type (%), 2018
  • Figure 6-1: Metformin - Recommended Initial, Maintenance & Maximum Dose of Immediate Release Tablet for Adults (mg/day), January'2020
  • Figure 6-2: Metformin - Recommended Initial & Maximum Dose of Extended Release Tablet for Adults (mg/day), January'2020
  • Figure 6-3: Metformin - Recommended Initial & Maximum Dose of Immediate Release Tablet for Pediatrics (mg/day), January'2020
  • Figure 6-4: Metformin - Recommended Initial & Maximum Dose of Extended Release Tablet for Pediatrics (mg/day), January'2020
  • Figure 6-5: Saudi Arabia - Price for 50 Tablet Supply & Price per unit of 500mg Glucophage Tablet (US$/SAR), January'2020
  • Figure 6-6: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of 850mg Glucophage Tablet (US$/ SAR), January'2020
  • Figure 6-7: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of 1gm Glucophage Tablet (US$/ SAR), January'2020
  • Figure 6-8: Saudi Arabia - Price for 30, 60 & 90 Tablet Supply & Price per unit of 500mg Glucare XR Tablet (US$/SAR), January'2020
  • Figure 6-9: Saudi Arabia - Price for 30 & 60 Tablet Supply & Price per unit of 750mg Glucare XR Tablet (US$/SAR), January'2020
  • Figure 6-10: Saudi Arabia - Price for 60 Tablet Supply & Price per unit of 1000mg Glucare XR Tablet (US$/SAR), January'2020
  • Figure 6-11: Saudi Arabia - Price for 50 Tablet Supply & Price per unit of 500mg Dimetor Tablet (US$/SAR), January'2020
  • Figure 6-12: Saudi Arabia - Price for 50 Tablet Supply & Price per unit of 850mg Dimetor Tablet (US$/SAR), January'2020
  • Figure 6-13: Saudi Arabia - Price for 30 & 60 Tablet Supply & Price per unit of 750mg Formit XR Tablet (US$/SAR), January'2020
  • Figure 6-14: Gliclazide - Recommended Initial & Maximum Dose for Adults (mg/day), January'2020
  • Figure 6-15: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Diamicron MR Tablet (US$/SAR), January'2020
  • Figure 6-16: Saudi Arabia - Price for 20 Tablet Supply & Price per unit Glaze 80mg Tablet (US$/SAR), January'2020
  • Figure 6-17 Saudi Arabia - Price for 60 Tablet Supply & Price per unit Glaze 80mg Tablet (US$/SAR), January'2020
  • Figure 6-18: Saudi Arabia - Price for 30 Tablet Supply & Price per unit Debacron 80mg Tablet (US$/SAR), January'2020
  • Figure 6-19: Glimepiride - Recommended Initial & Maximum Dose for Adults (mg/day), January'2020
  • Figure 6-20: Saudi Arabia - Price for 30 Tablet Supply of Various Dose Regimen of Amaryl Tablet (US$/SAR), January'2020
  • Figure 6-21: Saudi Arabia - Price per unit of Various Dose Regimen of Amaryl Tablet (US$/SAR), January'2020
  • Figure 6-22: Saudi Arabia - Price for 30 Tablet Supply of Various Dose Regimen of Glim Tablet (US$/SAR), January'2020
  • Figure 6-23: Saudi Arabia - Price per unit of Various Dose Regimen of Glim Tablet (US$/SAR), January'2020
  • Figure 6-24: Saudi Arabia - Price for 30 Tablet Supply of Various Dose Regimen of Glorion Tablet (US$/SAR), January'2020
  • Figure 6-25: Saudi Arabia - Price per unit of Various Dose Regimen of Glorion Tablet (US$/SAR), January'2020
  • Figure 6-26: Glibenclamide - Recommended Minimum & Maximum Initial Dose for Adults (mg/day), January'2020
  • Figure 6-27: Glibenclamide - Recommended Minimum & Maximum Maintenance Dose for Adults (mg/day), January'2020
  • Figure 6-28: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Daonil Tablet (US$/SAR), January'2020
  • Figure 6-29: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Glibil Tablet (US$/SAR), January'2020
  • Figure 6-30: Saudi Arabia - Price for 100 Tablet Supply & Price per unit of Apo-Glyburide Tablet (US$/SAR), January'2020
  • Figure 6-31: Vildagliptin - Recommended Dose in Combinational & Monotherapy for Type-2 Diabetes Treatment (mg/day), January'2020
  • Figure 6-32: Saudi Arabia - Price for 28 & 56 Tablet Supply & Price per unit of Galvus 50mg Tablet (US$/SAR), January'2020
  • Figure 6-33: Saudi Arabia - Price for 28 & 56 Tablet Supply & Price per unit of Valdatin 50mg Tablet (US$/SAR), January'2020
  • Figure 6-34: Saudi Arabia - Price for 28 & 56 Tablet Supply & Price per unit of Jalra 50mg Tablet (US$/SAR), January'2020
  • Figure 6-35: Onglyza - Patent Issue & Expiration Year
  • Figure 6-36: Saxagliptin - Recommended Minimum & Maximum Daily Dose (mg/day), January'2020
  • Figure 6-37: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Onglyza 2.5mg Tablet (US$/SAR), January'2020
  • Figure 6-38: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Onglyza 5mg Tablet (US$/SAR), January'2020
  • Figure 6-39: Januvia - Patent Issue & Expiration Year
  • Figure 6-40: Saudi Arabia - Price for 28 Tablet Supply & Price per unit of Januvia 100mg Tablet (US$/SAR), January'2020
  • Figure 6-41: Saudi Arabia - Monthly & Annual Treatment Cost of Type-2 Diabetes using Januvia Tablet (US$/SAR), January'2020
  • Figure 6-42: Invokana - Patent Issue & Expiration Year
  • Figure 6-43: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Invokana Tablet (US$/SAR), January'2020
  • Figure 6-44: Invokana - Recommended Minimum & Maximum Dose for Adults (mg/day), January'2020
  • Figure 6-45: Forxiga - Recommended Minimum & Maximum Dose for Adults (mg/day), January'2020
  • Figure 6-46: Saudi Arabia - Price for 28 Tablet Supply & Price per unit of Forxiga Tablet (US$/SAR), January'2020
  • Figure 6-47: Jardiance - Patent Issue & Expiration Year
  • Figure 6-48: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Jardiance Tablet (US$/SAR), January'2020
  • Figure 6-49: Jardiance - Recommended Minimum & Maximum Initial Dose for Adults (mg/day), January'2020
  • Figure 6-50: Saudi Arabia - Price for 30 Tablet Supply & Price per unit of Novonorm Tablet (US$/SAR), January'2020
  • Figure 6-51: Repaglinide - Recommended Minimum & Maximum Initial Dose for Adults (mg/meal), January'2020
  • Figure 6-52: Pioglitazone - Recommended Minimum & Maximum Initial Dose for Adults (mg/meal), January'2020
  • Figure 6-53: Saudi Arabia - Price for 30 Tablet Supply of Actos 15mg & 30mg Tablet (US$/SAR), January'2020
  • Figure 6-54: Saudi Arabia - Price for 30 Tablet Supply of Glacera 15mg, 30mg & 45mg Tablet (US$/SAR), January'2020
  • Figure 6-55: Saudi Arabia - Price for 30 Tablet Supply of Glados 15mg, 30mg & 45mg Tablet (US$/SAR), January'2020
  • Figure 6-56: Saudi Arabia - Price for 30 Tablet Supply of Acarose 50mg & 100mg Tablet (US$/SAR), January'2020
  • Figure 6-57: Saudi Arabia - Price for 30 Tablet Supply of Glucobay 50mg & 100mg Tablet (US$/SAR), January'2020
  • Figure 6-58: Acarbose - Recommended Initial & Maintenance Dose for Adults (mg/day), January'2020
  • Figure 6-59: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Daonil M 250/1.25mg Tablet (US$/SAR), January'2020
  • Figure 6-60: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Daonil M 500/2.5mg Tablet (US$/SAR), January'2020
  • Figure 6-61: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Daonil M 500/5mg Tablet (US$/SAR), January'2020
  • Figure 6-62: Saudi Arabia - Price for 30 Tablet Supply of Diamet 250/2.5mg, 500/2.5mg & 500/5mg Tablet (US$/SAR), January'2020
  • Figure 6-63: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Glucovance 500/2.5mg Tablet (US$/SAR), January'2020
  • Figure 6-64: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Glucovance 500/5mg Tablet (US$/SAR), January'2020
  • Figure 6-65: Saudi Arabia - Price for 30 Tablet Supply & Price per Unit of Amaryl M 2/500mg Tablet (US$/SAR), January'2020
  • Figure 6-66: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Galvus Met 1000/50mg Tablet (US$/SAR), January'2020
  • Figure 6-67: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Galvus Met 850/50mg Tablet (US$/SAR), January'2020
  • Figure 6-68: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Jalra M 1000/50mg Tablet (US$/SAR), January'2020
  • Figure 6-69: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of Jalra M 850/50mg Tablet (US$/SAR), January'2020
  • Figure 6-70: Saudi Arabia - Price for 56 Tablet Supply of 850/50mg & 1000/50mg Combinational Metformin/Sitagliptin Tablet (US$/SAR), January'2020
  • Figure 6-71: Kombiglyze XR - Patent Issue & Expiration Year
  • Figure 6-72: Saudi Arabia - Price for 30 Tablet Supply of 500/5mg, 1000/5mg & 1000/2.5mg Kombiglyze XR Tablet (US$/SAR), January'2020
  • Figure 6-73: Synjardy XR - Patent Issue & Expiration Year
  • Figure 6-74: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of 500/5mg, & 500/12.5mg Synjardy XR Tablet (US$/SAR), January'2020
  • Figure 6-75: Saudi Arabia - Price for 60 Tablet Supply & Price per Unit of 1000/5mg, & 1000/12.5mg Synjardy XR Tablet (US$/SAR), January'2020
  • Figure 6-76: Xigduo XR - Patent Issue & Expiration Year
  • Figure 6-77: Saudi Arabia - Price for 56 Tablet Supply & Price per Unit of 500/5mg Xigduo XR Tablet (US$/SAR), January'2020
  • Figure 6-78: Saudi Arabia - Price for 28 Tablet 500/10mg, 1000/5mg & 1000/10mg Xigduo XR Tablet (US$/SAR), January'2020
  • Figure 7-1: Lantus - Patent Issue & Expiration Year
  • Figure 7-2: Saudi Arabia - Price for 10ml Vial & Price per ml of Lantus (US$/SAR), January'2020
  • Figure 7-3: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Lantus (US$/SAR), January'2020
  • Figure 7-4: Saudi Arabia - Price for 10ml Vial & Price per ml of Humulin 70/30 (US$/SAR), January'2020
  • Figure 7-5: Saudi Arabia - Price for 10ml Vial & Price per ml of Humulin N-NPH (US$/SAR), January'2020
  • Figure 7-6: Saudi Arabia - Price for 10ml Vial & Price per ml of Humalog (US$/SAR), January'2020
  • Figure 7-7: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Humalog (US$/SAR), January'2020
  • Figure 7-8: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Humalog Mix 25 & 50 (US$/SAR), January'2020
  • Figure 7-9: Saudi Arabia - Price for 10ml Vial & Price per ml of Mixtard 30 (US$/SAR), January'2020
  • Figure 7-10: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Mixtard 40 Novolet (US$/SAR), January'2020
  • Figure 7-11: Saudi Arabia - Price for a 5 Cartridge Supply & Price per Cartridge of Mixtard 50 HM Novolet (US$/SAR), January'2020
  • Figure 7-12: Apidra - Patent Issue & Expiration Year
  • Figure 7-13: Saudi Arabia - Price for a 5 Vial Supply & Price per Vial of Apidra (US$/SAR), January'2020
  • Figure 7-14: Saudi Arabia - Price for 10ml Vial & Price per ml of Insulatard (US$/SAR), January'2020
  • Figure 8-1: Saudi Arabia - Diabetes Device Market Opportunity (US$ Million), 2019-2025
  • Figure 8-2: Saudi Arabia - Number of Insulin Users (Million), 2019-2025
  • Figure 9-1: Saudi Arabia - Price for Supply of 90 & Price per unit of 8 mm BD Ultra-fine Insulin Syringe 31G, 1/2cc (US$/SAR), January'2020
  • Figure 9-2: Saudi Arabia - Price for Supply of 100 & Price per unit of 8 mm BD Ultra-fine Insulin Syringe 31G, 3/10cc (US$/SAR), January'2020
  • Figure 9-3: Saudi Arabia - Price for Supply of 90 & Price per unit of 6 mm BD Ultra-fine Insulin Syringe 31G, 3/10cc (US$/SAR), January'2020
  • Figure 9-4: Saudi Arabia - Price for Supply of 90 & Price per unit of 0.5 inch BD Ultra-fine Insulin Syringe 30G, 3/10cc (US$/SAR), January'2020
  • Figure 9-5: Saudi Arabia - Price for Supply of 100 Care Touch 28G, 29G, 30G & 31G Insulin Syringe (US$/SAR), January'2020
  • Figure 9-6: Saudi Arabia - Insulin Syringe Consumption by 20% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-7: Saudi Arabia - Insulin Syringe Consumption by 30% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-8: Saudi Arabia - Insulin Syringe Consumption by 40% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-9: Saudi Arabia - Insulin Syringe Consumption by 50% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-10: Saudi Arabia - Insulin Pen Market Opportunity (US$ Million), 2019-2025
  • Figure 9-11: Commercially Available Insulin Pens
  • Figure 9-12: Saudi Arabia - Insulin Pen Consumption by 20% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-13: Saudi Arabia - Insulin Pen Consumption by 30% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-14: Saudi Arabia - Insulin Pen Consumption by 40% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-15: Saudi Arabia - Insulin Pen Consumption by 50% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-16: Saudi Arabia - Insulin Pen Consumption by 60% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-17: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lispro Containing Humalog Kwikpen (US$/SAR), January'2020
  • Figure 9-18: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lispro & Protamine Containing Humalog Kwikpen (US$/SAR), January'2020
  • Figure 9-19: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Novomix Flexpen (US$/SAR), January'2020
  • Figure 9-20: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Novorapid Flexpen (US$/SAR), January'2020
  • Figure 9-21: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lemevir Flexpen (US$/SAR), January'2020
  • Figure 9-22: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of Lantus Solostar (US$/SAR), January'2020
  • Figure 9-23: Saudi Arabia - Price for 3 & 5 Pens Supply & Price per Pen of Toujeo Solostar (US$/SAR), January'2020
  • Figure 9-24: Saudi Arabia - Price for 3 & 5 Pens Supply & Price per Pen of Toujeo Solostar 100,33mcg/ml (US$/SAR), January'2020
  • Figure 9-25: Saudi Arabia - Price for 3 & 5 Pens Supply & Price per Pen of Toujeo Solostar 100,50mcg/ml (US$/SAR), January'2020
  • Figure 9-26: Saudi Arabia - Price of Novopen 3, 4, 5 & Novopen Echo (US$/SAR), January'2020
  • Figure 9-27: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 100units/ml Tresiba Flextouch pen (US$/SAR), January'2020
  • Figure 9-28: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US$/SAR), January'2020
  • Figure 9-29: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US$/SAR), January'2020
  • Figure 9-30: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US$/SAR), January'2020
  • Figure 9-31: Saudi Arabia - Price for 5 Pens Supply & Price per Pen of 200units/ml Tresiba Flextouch pen (US$/SAR), January'2020
  • Figure 9-32: Types of Insulin Pumps
  • Figure 9-33: Saudi Arabia - Insulin Pump Consumption by 5% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-34: Saudi Arabia - Insulin Pump Consumption by 10% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-35: Saudi Arabia - Insulin Pump Consumption by 15% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-36: Saudi Arabia - Insulin Pump Consumption by 20% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-37: Saudi Arabia - Insulin Jet Injectors Consumption by 5% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-38: Saudi Arabia - Insulin Jet Injectors Consumption by 10% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-39: Saudi Arabia - Insulin Jet Injectors Consumption by 15% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-40: Saudi Arabia - Insulin Jet Injectors Consumption by 20% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 9-41: Saudi Arabia - Insulin Jet Injectors Consumption by 25% of Total Insulin Delivery Device Users (000'), 2019-2025
  • Figure 10-1: Saudi Arabia - Commercially Available Glucose Monitoring Devices
  • Figure 10-2: Saudi Arabia - Glucose Monitoring Device Market Opportunity (US$ Million), 2019-2025
  • Figure 10-3: Saudi Arabia - Price for Various Accu-Chek Blood glucose Monitoring Device (US$/SAR), January'2020
  • Figure 10-4: Saudi Arabia - Price for Various Supplies of Accu-Chek Performa Test Strips (US$/SAR), January'2020
  • Figure 10-5: Saudi Arabia - Price for 50 Strips & Price for Single Test Strip of Accu-Chek Active (US$/SAR), January'2020
  • Figure 10-6: Saudi Arabia - Price for 50 Strips & Price for Single Test Strip of Accu-Chek Instant (US$/SAR), January'2020
  • Figure 10-7: Saudi Arabia - Price for Supply of 50 & Price for Single Lancet of Accu-Chek Softclinx (US$/SAR), January'2020
  • Figure 10-8: Saudi Arabia - Price for Supply of 102 & 204 Lancets of Accu-Chek Fastclinx (US$/SAR), January'2020
  • Figure 10-9: Saudi Arabia - Price for Abbott's Freestyle Optimum Glucometer, Test Strip & Lancets (US$/SAR), January'2020
  • Figure 10-10: Saudi Arabia - Price for Bayes Contour & Easy Max Glucometer (US$/SAR), January'2020
  • Figure 10-11: Saudi Arabia - Price for 50 Lancet Supply and Price per unit of Bayes Contour Test Strips (US$/SAR), January'2020
  • Figure 10-12: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 40% of Diagnosed Diabetics (Million), 2019-2025
  • Figure 10-13: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 50% of Diagnosed Diabetics (Million), 2019-2025
  • Figure 10-14: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 60% of Diagnosed Diabetics (Million), 2019-2025
  • Figure 10-15: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 70% of Diagnosed Diabetics (Million), 2019-2025
  • Figure 10-16: Saudi Arabia - Self-Regulating Blood Glucose Monitor Consumption by 80% of Diagnosed Diabetics (Million), 2019-2025
  • Figure 10-17: Saudi Arabia - Price of Freestyle Libre Sensor & Receiver (US$/SAR), January'2020
  • Figure 10-18: Saudi Arabia - Price of Dexcom G5 Sensor, Receiver & Transmitter (US$/SAR), January'2020
  • Figure 10-19: Saudi Arabia - Price of Dexcom G6 Sensor, Receiver & Transmitter (US$/SAR), January'2020
  • Figure 10-20: Saudi Arabia - Price of a Supply of 3 Sensor & Price for Single Sensor of Dexcom G6 (US$/SAR), January'2020
  • Figure 10-21: Saudi Arabia - Price for a Supply of 5 Sensor & Price for Single Sensor of Guardian Sensor 3 (US$/SAR), January'2020
  • Figure 10-22: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 10% of Diagnosed Diabetics (000'), 2019-2025
  • Figure 10-23: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 20% of Diagnosed Diabetics (000'), 2019-2025
  • Figure 10-24: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 30% of Diagnosed Diabetics (000'), 2019-2025
  • Figure 10-25: Saudi Arabia - Continuous Blood Glucose Monitor Consumption by 40% of Diagnosed Diabetics (000'), 2019-2025
  • Figure 11-1: Saudi Arabia - Total Number of Clinical Trial v/s Diabetes related Trials, 2020
  • Figure 11-2: Saudi Arabia - Number of Diabetes related Clinical Trials by Development Phase, 2020
  • Figure 11-3: Saudi Arabia - Number of Diabetes related Clinical Trials by Development Phase, 2020
  • Figure 11-4: Saudi Arabia - Number of Clinical Trials by Status, 2019
  • Figure 13-1: Saudi Arabian Diabetes Market Drivers
  • Figure 13-2: Challenges for Saudi Arabia Diabetes Market
Back to Top